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background: The cardiorenal syndrome 1 is associated with poor patient outcomes. Currently, two treatment options exist: medical management 
with diuretics, vasodilators, and inotropes and ultrafiltration to remove salt and water. Controversy exists about which option is better, but little is 
known when diuretics fail and the severity of kidney dysfunction necessitates the need for renal replacement therapy for both volume removal and 
solute clearance.
Methods: We retrospectively analyzed 37 consecutive patients admitted for acute decompensated heart failure from 2005-2013 who required 
continuous renal replacement therarpy (CRRT) for volume removal and solute clearance.
results: We observed 62% in-hospital mortality rate in our cohort. When comparing renal and cardiovascular variables between the survivors with 
the deceased at baseline, admission, and initiation of CRRT, the only significant differences were the survivors were less likely to need vasopressors. 
Logistic regression analysis revealed an odds ratio (OR) of 15.9 in univariate analysis and 13.5 in a multivariant analysis for in-hospital mortality 
when vasopressors were used. Patients with right ventricular (RV) dysfunction had lower in-hospital mortality (45%) than those with left ventricular 
(LV) function (62%). However, the addition of vasopressors increased mortality to 71% in RV dysfunction group and 94% in LV dysfunction group. Age 
>70 was associated with 100% in-hospital mortality. Finally, 29% of the survivors required hemodialysis after discharge and a median survival of ten 
months was observed.
conclusions: Our single center study demonstrated rescue therapy using CRRT in refractory cardiorenal syndrome was associated with high rates 
of death especially when vasopressors were used and poor long term prognosis.
